Sell2Wales.gov.wales uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies.

Accept cookies Cookie Settings

View Notice

The buyer is not using this website to administer the notice. To record your interest or obtain additional information or documents please find instructions within the Full Notice Text. (NOTE: Contract Award Notices and Prior Information Notices do not normally require a response)

Add notice to my Sell2Wales Interest List

Notice Details

Title: Managed Service for the Bacterial Screening of Platelets
OCID: ocds-h6vhtk-03590d
Published by: NHS Blood and Transplant
Authority ID: AA72163
Publication Date: 05/08/2022
Deadline Date:
Deadline Time:
Notice Type: Prior Information Notice
Has Documents: No
Has SPD: No
Abstract:

NHSBT requires a direct contractual relationship with either the manufacturer or any other economic operator for a complete end-to-end integrated solution, which must include all the necessary equipment, installation, maintenance, consumables, reagents, software, including an inter-operability provision with NHSBT’s existing IT infrastructure, and an overall on-going support mechanism that may be required to carry out the necessary testing as stated below. All invitro diagnostic medical devices, for example, instruments, consumables, and reagents must be CE/UKCA marked. GB will continue to recognise CE marking under the IVDD or IVDR until 30 June 2023 and from 1 July 2023 devices placed on the GB market must be UKCA marked under the UK MDR 2002 as amended. The end-to-end solution must be capable of producing test results in a format that can be utilised by NHSBT’s host IT system (PULSE) without the need for changes to PULSE. <br/><br/>NHSBT are looking for a fully integrated, high throughput, automated bacterial screening system which can detect bacterial contamination in platelet components. The system will be used in Filton (Bristol), Manchester and Colindale (London) where approximately 270,000 adult therapeutic doses of platelets are manufactured each year. NHSBT are seeking to engage with suppliers who can provide this. The system must be CE/UKCA marked. Additional requirements to be included with the managed service contract include:<br/>- continuous calibrated temperature monitoring<br/>- ability to integrate with NHSBT information management system<br/>- alerting software (for positive results, hardware errors, temperature excursions)<br/>- consumables (including, but not limited to, sterile sampling connecting devices)<br/><br/>All test protocols must be in accordance with the Guidelines for the Blood Transfusion service in the United Kingdom (https://www.transfusionguidelines.org/red-book) and the Good Practice Guidelines for Blood Establishments that are Required to Comply with Directive 2005/62/EC. These are published in the 20th edition of the Guide to the preparation, use and quality assurance of blood components. <br/><br/><br/>It is NHSBTs’ intention to engage with the market to gather detailed information about the market capabilities. The format for this will be communicated to those that respond to this PIN. Virtual Supplier Engagement days are likely to be a Webinar followed by individual supplier presentation days. Expressions of interest should be e-mailed to jo.murphy@nhsbt.nhs.uk by no later than 12:00 hours on 25th August 2022.

Prior information notice

This notice is for prior information only

Directive 2014/24/EU - Public Sector Directive

Directive 2014/24/EU

Section I: Contracting authority

I.1) Name and addresses

NHS Blood and Transplant

NHS Blood and Transplant

500 North Bristol Park

Bristol

BS34 7QH

UK

Contact person: Jo Murphy

Telephone: +44 1179212718

E-mail: jo.murphy@nhsbt.nhs.uk

NUTS: UKK11

Internet address(es)

Main address: https://www.nhsbt.nhs.uk/

Address of the buyer profile: https://www.nhsbt.nhs.uk/

I.3) Communication

Additional information can be obtained from the abovementioned address


Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at:

https://health-family.force.com/s/Welcome


I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Managed Service for the Bacterial Screening of Platelets

II.1.2) Main CPV code

85111810

 

II.1.3) Type of contract

Services

II.1.4) Short description

This Prior Information Notice (PIN) follows 2021/S 000-013561 released on the 16th June 2021 and all information herein supersedes that of 2021/S 000-013561.<br/><br/>This Prior Information Notice (PIN) is separate to any tender opportunity and not related in any form whatsoever to any subsequent activity that NHSBT may wish to pursue. The purpose of this PIN is to consult the market to improve NHSBT’s knowledge on the status of manufacturer(s) or economic operator(s) that can supply a commercially available automated, high-throughput automated bacterial screening system which can detect bacterial contamination in platelet components. <br/>NHSBT needs to gauge market interest in a new provision of this service. It is the intention of NHSBT to further consult and engage with only those manufacturer(s) and economic operator(s) who meet the outline requirements.

II.1.5) Estimated total value

Value excluding VAT: 31 200 000.00  GBP

II.1.6) Information about lots

This contract is divided into lots: No

II.2) Description

II.2.2) Additional CPV code(s)

33696200

38434520

48921000

71632000

85111810

71600000

85146000

71900000

33698100

II.2.3) Place of performance

NUTS code:

UK

II.2.4) Description of the procurement

NHSBT requires a direct contractual relationship with either the manufacturer or any other economic operator for a complete end-to-end integrated solution, which must include all the necessary equipment, installation, maintenance, consumables, reagents, software, including an inter-operability provision with NHSBT’s existing IT infrastructure, and an overall on-going support mechanism that may be required to carry out the necessary testing as stated below. All invitro diagnostic medical devices, for example, instruments, consumables, and reagents must be CE/UKCA marked. GB will continue to recognise CE marking under the IVDD or IVDR until 30 June 2023 and from 1 July 2023 devices placed on the GB market must be UKCA marked under the UK MDR 2002 as amended. The end-to-end solution must be capable of producing test results in a format that can be utilised by NHSBT’s host IT system (PULSE) without the need for changes to PULSE. <br/><br/>NHSBT are looking for a fully integrated, high throughput, automated bacterial screening system which can detect bacterial contamination in platelet components. The system will be used in Filton (Bristol), Manchester and Colindale (London) where approximately 270,000 adult therapeutic doses of platelets are manufactured each year. NHSBT are seeking to engage with suppliers who can provide this. The system must be CE/UKCA marked. Additional requirements to be included with the managed service contract include:<br/>- continuous calibrated temperature monitoring<br/>- ability to integrate with NHSBT information management system<br/>- alerting software (for positive results, hardware errors, temperature excursions)<br/>- consumables (including, but not limited to, sterile sampling connecting devices)<br/><br/>All test protocols must be in accordance with the Guidelines for the Blood Transfusion service in the United Kingdom (https://www.transfusionguidelines.org/red-book) and the Good Practice Guidelines for Blood Establishments that are Required to Comply with Directive 2005/62/EC. These are published in the 20th edition of the Guide to the preparation, use and quality assurance of blood components. <br/><br/><br/>It is NHSBTs’ intention to engage with the market to gather detailed information about the market capabilities. The format for this will be communicated to those that respond to this PIN. Virtual Supplier Engagement days are likely to be a Webinar followed by individual supplier presentation days. Expressions of interest should be e-mailed to jo.murphy@nhsbt.nhs.uk by no later than 12:00 hours on 25th August 2022.

II.3) Estimated date of publication of contract notice:

01/11/2022

Section IV: Procedure

IV.1) Description

IV.1.8) Information about Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

Section VI: Complementary information

VI.5) Date of dispatch of this notice

04/08/2022


Information added to the notice since publication.

Additional information added to the notice since it's publication.
No further information has been uploaded.
Main Contact: jo.murphy@nhsbt.nhs.uk
Admin Contact: N/a
Technical Contact: N/a
Other Contact: N/a

Commodity Categories

Commodity Categories
IDTitleParent Category
48921000Automation systemOffice automation software package
38434520Blood analysersAnalysers
85111810Blood analysis servicesHospital services
33696200Blood-testing reagentsReagents and contrast media
71900000Laboratory servicesArchitectural, construction, engineering and inspection services
33698100Microbiological culturesClinical products
85146000Services provided by blood banksMiscellaneous health services
71632000Technical testing servicesTechnical inspection and testing services
71600000Technical testing, analysis and consultancy servicesArchitectural, construction, engineering and inspection services

Delivery Locations

Delivery Locations
IDDescription
100UK - All

Alert Region Restrictions

The buyer has restricted the alert for this notice to suppliers based in the following regions.

Alert Region Restrictions
There are no alert restrictions for this notice.

Copyright © Sell2Wales